Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 2/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17071865 | 0.87 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HPGDSCN4A | |
| SCHEMBL25833637 | 0.87 | IDO1 (0.32) | — | |
| SCHEMBL16770966 | 0.87 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HPGDSCN4A | |
| SCHEMBL16770758 | 0.87 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HPGDSCN4A | |
| SCHEMBL16959011 | 0.81 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3TRPM8EPAS1 | |
| SCHEMBL18713530 | 0.79 | USP2 (0.38) | SLC6A2TRPM8EPAS1GPR139HPGD | |
| SCHEMBL25609098 | 0.79 | TRPM8 (0.38) | TRPM8EPAS1GPR139RAPGEF4 | |
| SCHEMBL20993152 | 0.76 | TRPM8 (0.34) | SLC6A2TRPM8GPR139RAPGEF4 | |
| SCHEMBL2393968 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL25833265 | 0.75 | TRPM8 (0.39) | SLC6A2SLC6A4TRPM8GPR139ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | SLC6A2 1803/4885SLC6A4 2807/4885SLC6A3 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.